Welcome to our dedicated page for Merck & Co SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Warden Kathy J reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Kathy J. Warden reported a compensation-related update rather than an open-market trade. She received a grant of 1,853.0997 phantom stock units tied 1-for-1 to Merck common stock at a reference value of $118.7200 per unit, bringing her phantom stock holdings to 17,890.2917 units. These units will be settled entirely in cash after her service ends, under the Plan for Deferred Payment of Directors' Compensation. Separately, she reported direct ownership of 500 shares of Merck common stock, which includes shares accumulated through dividend reinvestment transactions.
Karsanbhai Surendralal Lanca reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Karsanbhai Surendralal Lanca reported a compensation-related award of phantom stock units rather than an open-market trade. On 2026-05-29, he received 1,853.0997 phantom stock units, bringing his total phantom stock holdings to 5,392.3427 units.
Each phantom unit is linked on a 1-for-1 basis to Merck common stock but will be settled 100% in cash after his service ends, following a distribution schedule under the Plan for Deferred Payment of Directors' Compensation. He also reports direct ownership of 1 share of Merck common stock, with holdings including shares from dividend reinvestment transactions.
Merck & Co., Inc. director Mary Ellen Coe reported a routine compensation-related change in holdings. She received a grant of 1,853.0997 phantom stock units, each on a 1-for-1 basis referencing Merck common stock. These phantom units are to be settled 100% in cash upon her termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After the grant, she holds 31,765.6386 phantom stock units and 10 shares of Merck common stock, with share holdings including amounts acquired through dividend reinvestment transactions.
Merck & Co., Inc. director Inge G. Thulin reported updated holdings that include a new grant of phantom stock units. On 2026-05-29, the director acquired 1,853.0997 phantom stock units, each linked on a 1-for-1 basis to Merck common stock. These phantom units are designed as deferred compensation and will be settled 100% in cash after the director’s termination of service, following a distribution schedule elected under the Plan for Deferred Payment of Directors' Compensation. After this grant, the director holds 27,469.7107 phantom stock units and 2,932.8610 shares of common stock, with the common stock holdings including shares acquired through dividend reinvestment transactions.
Seidman Christine E reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Christine E. Seidman reported a compensation-related change in her holdings. She received an award of 1,853.0997 phantom stock units tied to Merck common stock at a reference price of $118.72 per unit. After this grant, her phantom stock balance is 21,228.0394 units, which will be settled 100% in cash after her service ends under the company’s deferred compensation plan. Separately, she reports holding 100 shares of Merck common stock directly, including shares accumulated through dividend reinvestment.
RUSSO PATRICIA F reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Patricia F. Russo received 1,853.0997 phantom stock units as a grant of deferred compensation tied to Merck common stock. The phantom stock units are to be settled 100% in cash upon her termination of service under the Plan for Deferred Payment of Directors' Compensation. After this award, she holds 62,390.7517 phantom stock units and 13,148 shares of Merck common stock directly.
Merck & Co., Inc. director Paul Rothman reported compensation-related equity activity. He received a grant of 1,853.0997 phantom stock units tied to Merck common stock at a reference price of $118.7200 per unit.
After this grant, his phantom stock holdings total 34,944.9417 units, which are to be settled 100% in cash upon his termination of service under the Plan for Deferred Payment of Directors' Compensation. He also reports direct ownership of 100 shares of Merck common stock, including shares acquired through dividend reinvestment transactions.
Merck & Co., Inc. director Stephen Mayo reported a compensation-related award of phantom stock units linked to the company’s common stock. He received 1,853.0997 phantom stock units, which are tied 1-for-1 to Merck common shares and are to be settled 100% in cash after his service ends under a deferred compensation plan. Following this award, he holds 14,824.5202 phantom stock units and 100 shares of Merck common stock, with the share holdings including amounts acquired through dividend reinvestment transactions.
LAVIZZO-MOUREY RISA J reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Risa J. Lavizzo-Mourey reported a compensation-related award of phantom stock units rather than a market trade. She received 1,853.0997 phantom stock units tied on a 1-for-1 basis to Merck common stock at a reference price of $118.72 per unit, increasing her phantom stock balance to 17,749.3517 units. These units are designed to be settled 100% in cash after her service ends, under the Plan for Deferred Payment of Directors' Compensation. The filing also notes she directly holds 1,000 shares of Merck common stock, including shares accumulated through dividend reinvestment.
GLOCER THOMAS H reported acquisition or exercise transactions in this Form 4 filing.
Merck & Co., Inc. director Thomas H. Glocer reported updated holdings, including a new grant of phantom stock units tied to the company’s common shares. He received 1853.0997 phantom stock units, each tracked on a 1-for-1 basis to Merck common stock and awarded at a reference price of $118.7200 per unit.
Following this grant, Glocer holds 110911.7587 phantom stock units, which are to be settled entirely in cash after his termination of service under the Plan for Deferred Payment of Directors' Compensation. His direct common stock holdings total 5100.0000 shares, including shares accumulated through dividend reinvestment transactions.